Article

A search for overlapping genetic susceptibility loci between non-Hodgkin lymphoma and autoimmune diseases

Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, USA.
Genomics (Impact Factor: 2.79). 03/2011; 98(1):9-14. DOI: 10.1016/j.ygeno.2011.03.007
Source: PubMed

ABSTRACT Non-Hodgkin lymphoma (NHL) is a hematological malignancy of the immune system, and, as with autoimmune and inflammatory diseases (ADs), is influenced by genetic variation in the major histocompatibility complex (MHC). Persons with a history of specific ADs also have increased risk of NHL. As the coexistence of ADs and NHL could be caused by factors common to both diseases, here we examined whether some of the associated genetic signals are shared. Overlapping risk loci for NHL subytpes and several ADs were explored using data from genome-wide association studies. Several common genomic regions and susceptibility loci were identified, suggesting a potential shared genetic background. Two independent MHC regions showed the main overlap, with several alleles in the human leukocyte antigen (HLA) class II region exhibiting an opposite risk effect for follicular lymphoma and type I diabetes. These results support continued investigation to further elucidate the relationship between lymphoma and autoimmune diseases.

Full-text

Available from: Lucia Conde, May 06, 2015
0 Followers
 · 
190 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The simultaneous presence of hematological malignancies and sarcoidosis, defined as sarcoidosis-lymphoma syndrome, has been reported in 79 patients in the literature to date. The majority of these patients were affected by sarcoidosis and developed non-Hodgkin lymphoma or acute leukemia after 1-2 years; however, in <20 cases the malignancy developed first. This report presents the case of an 83-year-old male with a clinical history of Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma. The patient developed sarcoidosis 10 years after the first diagnosis, which caused the diagnostic work-up and differential diagnosis between a lymphoma relapse and de novo sarcoidosis to be challenging.
    Oncology letters 09/2014; 8(3):1299-1301. DOI:10.3892/ol.2014.2241 · 0.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The data of genome-wide association analysis suggest that human 6p21.3 chromosomal region (localization of HLA genes) contains polymorphic loci infl uencing the risk of developing non-Hodgkin's lymphomas. We analyzed association of rs2647012 and rs805288 loci with the risk for non-Hodgkin's malignant lymphomas in the population of Western Siberia. Allele and genotype frequencies were determined in the group of 298 patients and in the control group including 551 individuals. Subgroups of diffuse large B-cell lymphoma (86 patients) and follicular lymphoma (25 patients) were analyzed separately. An association of rs2647012 А/А genotype with increased risk of the disease (OR = 2.78, p = 0.002) was detected in the subgroup of diffuse large B-cell lymphoma.
    Bulletin of Experimental Biology and Medicine 06/2014; 157(2). DOI:10.1007/s10517-014-2520-2 · 0.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The cumulative risk of NHL in Sweden by age 80 years has increased to 1.1 in women and 1.6% in men in 2011. Increased risk of non-Hodgkin lymphoma (NHL) associated with personal histories of some autoimmune diseases (ADs) are known. It is unclear whether there are other NHL-related ADs and whether this association holds across different sex, age and year of diagnosis, or NHL histological subtypes. PATIENTS AND METHODS: Over an average of 9.4-year (maximum 47 years) follow-up of 878,161 patients diagnosed in 1964-2010 with 33 different ADs, 3,096 subsequent NHL were diagnosed (data: Swedish Cancer Registry). RESULTS: Out of 33 studied ADs, 21 showed significantly increased risk of NHL; 6 of them tended to increase the risk and none significantly decreased it. The overall standardized incidence ratio (SIR) for NHL after ADs was 1.6 [novel findings: immune thrombocytopenic purpura (ITP)=7.5, polymyositis/dermatomyositis=4.1, primary biliary cirrhosis=3.9, myasthenia gravis=2.2, Behcet=1.7, rheumatoid fever=1.7, ulcerative colitis=1.5, polymyalgia rheumatica=1.4, and chronic rheumatic heart disease=1.4; confirmatory findings: autoimmune hemolytic anemia=27.2, Sjögren=4.9, Celiac=4.8, systemic lupus erythematosus=4.4, polyarteritis nodosa=2.9, discoid lupus erythematosus=2.7, sarcoidosis=2.6, Crohn=2.1, systemic sclerosis=2.1, rheumatoid arthritis=2.0, and Hashimoto/hypothyroidism and psoriasis=1.4]. SIR for NHL diagnosis before age 60 (2.2) was significantly higher than that in older ages (age≥60: 1.5). The SIRs in women or men and in period 1993-2010 or 1964-1992, were similar. Risk of all common NHL histology subtypes significantly increased after ADs (cutaneous/peripheral T-cell and anaplastic large T- and null cell=2.2; small B-cell lymphocytic=1.7; diffuse large B-cell=1.6; follicular and mantel cell=1.3). CONCLUSION: Many of 33 studied ADs (except for ankylosing spondylitis, diabetes type I graves/hyperthyroidism, multiple sclerosis, chorea minor, and pernicious anemia), especially when diagnosed at younger ages, were associated with higher risk of NHL. However, the absolute risk of NHL in many ADs is still small.
    Annals of Oncology 07/2014; 25(10). DOI:10.1093/annonc/mdu365 · 6.58 Impact Factor